27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Random Forest achieves the highest accuracy of 97% on clinical data, while CNN achieves the best overall performance of 94% in MRI-based staging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate and reproducible electroencephalography (EEG)-based classification of dementia remains a key challenge in computational neurodiagnostics. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia poses an on-going Canadian challenge due to an aging population, with cases projected to rise significantly by 2050. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Physical inactivity and low fitness have become global health concerns. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lewy body dementias (LBD), comprising dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), are defined by misfolded α-synuclein aggregation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The aging population is increasingly affected by both diabetes mellitus and hearing loss, two conditions that often coexist and can significantly impact quality of life. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings indicate that the burden of dementia is rising in East and Southeast Asia, with women showing a higher burden across all indicators. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There was a significant interaction between OSA and diagnosis for within- and between-DMN FC (p-values<0.05). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Amyloid pathology in aDS individuals is linked to frontal‐predominant atrophy without clear hypometabolism. 5 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MOLDI-MS identified eighty-five proteins represented by multiple tryptic peptides, twenty-five of which showed significant differences between DS and controls, confirmed by WB and ELISA analysis. 5 key findings →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is characterized by deficits in cognition, behavior, and intellectual functioning, and Mild Cognitive Impairment (MCI) refers to individuals whose cognitive impairment deviates from what is expected for their age but does not significantly interfere with daily activities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) represents an initial phase of memory or other cognitive function decline and is viewed as an intermediary stage between normal aging and Alzheimer's disease (AD), the most prevalent type of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
About one billion people worldwide are affected by neurologic disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The analyses supported stage-dependent remodeling of astrocyte-associated transcriptional and metabolic programs during disease progression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Event-related potentials (ERPs), particularly the P300 component, provide a noninvasive, cost-effective approach to probing neural dysfunction in Alzheimer's disease (AD) and mild cognitive impairment (MCI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Comparison of proteins between the three groups revealed significantly lower Aβ1-42, higher Tau and pTau protein expression in serum of patients with Alzheimer disease as compared to patients with mild cognitive impairment and controls. 4 key findings →
Participants: 96 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared with no testing, the CSF strategy yielded 0.011 additional life-years and 0.019 additional QALYs for an extra cost of THB2,589 (USD71), resulting in an ICER of THB132,961 (USD3,632) per QALY. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Altered β-amyloid (Aβ) homeostasis is a critical event triggering the shift from healthy aging to Alzheimer disease (AD) through the overproduction and impaired clearance of Aβ peptides. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Objetivo:Analisar criticamente o potencial dos exossomos sanguíneos associados a marcadores inflamatórios e ferramentas nanotecnológicas como biomarcadores hematológicos no diagnóstico precoce da Doença de Alzheimer (DA), enfatizando aplicações translacionais. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PFT is longer at CDR-SB ≤ 2.0 (1-2 years) and shorter at CDR-SB ≥ 5 (≤ 0.33) in the Alzheimer's Disease Neuroimaging Initiative cohort. 5 key findings →
Design: open-label trial Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
No statistically significant differences emerged between SDW and GW groups regarding baseline demographics, cognitive function, ADL, or neuropsychiatric symptoms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The four- and seven-class clustering solutions achieved high variance overlap with published microstate templates. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Pathophysiological differences separating small vessel disease (SVD) from Alzheimer's disease (AD) may alter treatment approach. 3 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →